Article Text

Download PDFPDF

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
  1. Sara M Mangsbo3,
  2. Sissela Broos2,
  3. Erika Gustafsson3,
  4. Christina Furebring1,
  5. Niina Veitonmäki1,
  6. Eva Dahlen1,
  7. Per Norlen1,
  8. Malin Lindstedt2,
  9. Thomas Tötterman3 and
  10. Peter Ellmark1,2
  1. Aff1 grid.432080.dAlligator Bioscience AB Lund Sweden
  2. Aff2 grid.4514.40000000109302361ImmunotechnologyLund University Lund Sweden
  3. Aff3 grid.8993.b0000000419369457Immunology, Genetics and PathologyUppsala University Uppsala Sweden

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

Local administration of immune activating antibodies may increase the efficacy and reduce the immune-related adverse events associated with systemic immunotherapy of cancer. Here we report the development of a fully human agonistic CD40 antibody (IgG1), ADC-1013, which has been optimized for local immunotherapy by increasing potency and tumor retention. ADC-1013 activates CD40 receptors on antigen-presenting cells such as dendritic cells, resulting in up-regulation of the co-stimulatory molecules CD80 and CD86, and induction of IL-12. In addition, ADC-1013 induces direct tumor killing of CD40+ tumors, e.g. via antibody-dependent cellular cytotoxicity (ADCC). The anti-tumor effects of ADC-1013 were first assessed in a bladder cancer model (EJ) in immunodeficient NSG mice. Significant anti-tumor responses were demonstrated, and further augmented in mice repopulated with human moDCs/T cells. To study the anti-tumor effects related to the immune activating properties of ADC-1013 in more detail, a human CD40 positive transgenic mouse (hCD40tg) in C57/BL-6 background was used. This transgenic mouse strain has an intact immune system and fully functional dendritic cells that are activated upon ADC-1013 treatment. Furthermore, the dendritic cells obtained from this strain are able to induce antigen specific T cell activation in vitro upon stimulation with ADC-1013. Importantly, treatment with ADC-1013 in a syngeneic bladder cancer (MB49) model, which is hCD40 negative, demonstrated that ADC-1013 induce significant tumor protection and long term immunity independent of direct tumor targeting. In addition, the anti-tumor immunity was shown to be T-cell dependent. To our knowledge, ADC-1013 represents the first immunomodulatory antibody optimized for local immunotherapy of cancer. It is currently in late pre-clinical development and will enter clinical trials in 2014.